Elvin Ahmadov

Koeln, NW 50931, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Identification of a broad and potent V3 glycan site bNAb targeting an N332gp120 glycan-independent epitope.

Identification of a broad and potent V3 glycan site bNAb targeting an N332gp120 glycan-independent epitope.

Journal: bioRxiv : the preprint server for biology

Published: September 18, 2025

Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.

Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapy.

Journal: bioRxiv : the preprint server for biology

Published: September 05, 2025

Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332gp120 glycan-independent epitope.

Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332gp120 glycan-independent epitope.

Journal: Nature immunology

Published: May 15, 2025

Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.

Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.

Journal: Nature immunology

Published: March 06, 2025

Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.

Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy.

Journal: Nature immunology

Published: March 06, 2025

Dynamics and durability of HIV-1 neutralization are determined by viral replication.

Dynamics and durability of HIV-1 neutralization are determined by viral replication.

Journal: Nature medicine

Published: February 26, 2023

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients.

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients.

Journal: Nature communications

Published: December 22, 2022

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.

Journal: RMD open

Published: August 03, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026